The bill establishes the Neurofibromatosis Disease Grant Program within the Florida Department of Health, aimed at advancing research and finding cures for neurofibromatosis through competitive grants. The program is funded by an annual appropriation of $5 million from the Legislature, which will be allocated for scientific and clinical research focused on new diagnostics, treatments, and cures. Grant applications can be submitted by universities and established research institutes in Florida, with a preference for proposals that encourage collaboration among various institutions and practitioners. The grants will be awarded based on scientific merit, as determined by a peer-reviewed process involving the Rare Disease Advisory Council.

Additionally, the bill outlines the ethical guidelines and conflict of interest policies that members of the Rare Disease Advisory Council and peer review panels must adhere to during the evaluation of grant applications. It prohibits council and panel members from participating in discussions or decisions regarding proposals from entities with which they have a personal or contractual relationship. The bill also allows for any unspent funds from the General Revenue Fund allocated to the program to be carried forward for up to five years if they are obligated or committed by the end of the fiscal year. The act is set to take effect on July 1, 2026.